US Patent Issued to Arrowhead Pharmaceuticals on Oct. 14 for "RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use" (Wisconsin, Illinois, California Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,442,002, issued on Oct. 14, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use" was invented by Michelle Ngai (Fitchburg, Wis.), Mark Majewski (Rockton, Ill.), Zhi-Ming Ding (Waunakee, Wis.), Agnieszka Glebocka (Madison, Wis.), Tao Pei (Middleton, Wis.), James C. Hamilton (Sierra Madre, Calif.) and Grigoriy Shekhtman (Los Angeles).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Activin Receptor-Like Kinase 7 (ALK7) gene. T...